

RECEIVED
CENTRAL FAX CENTER
JUL 18 2006

REMARKS


On July 1, 2004, the Examiner issued a Restriction Requirement. Applicants elected Group I and SEQ ID NO:1 with traverse in a timely manner. A further Restriction Requirement was issued on December 23, 2004. This filing is responsive to the Restriction Requirement dated December 23, 2004.

In the new Restriction Requirement, the Examiner has further required the identification of primer or probe sequences (from SEQ ID NOs: 12-51) that correspond to elected SEQ ID NO:1. In response, Applicants elect SEQ ID NOs: 40, 42, 43, and 44 (see Example 2; page 39, lines 13-16), that correspond to SEQ ID NO:1.

Applicants are amending claims 2 and 3 to correspond to the restriction requirement dated July 1, 2004. Applicants are amending claims 17 and 28 for clarity. Support for the amended claims can be found in the specification as originally filed on page 25, lines 4-15; and page 9, lines 14-22 and original claims. Applicants are amending claim 33 to be dependent on claim 28. Support for the amended claim can be found in the specification as originally filed on page 23, lines 6-17 and original claims.

Applicants respectfully request withdrawal of the restriction requirement and allowance of the claims. Applicants request that any other fee required for consideration of this submission be charged to undersigned's Deposit Account No. 13-3372, from which the undersigned is authorized to draw.

Respectfully submitted,


Susan M. Pellegrino
Attorney for Applicants
Reg. No. 48,972

Date: July 18, 2006

Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516-4175
Telephone: (203) 812-6450
Facsimile: (203) 812-6459